These alterations may be highly significant also for in vivo NK cell cytotoxic activity against DLBCL cells, and as such, may impact rituximab-based therapy efficacy.
← all excerpts
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.
1
—
—